Poster, Podium & Video Sessions
Presentation Authors: Emily Durden*, Bethesda, MD, David Walker, Northbrook, IL, Stephani Gray, Robert Fowler, Paul Juneau, Bethesda, MD, Katherine Gooch, Northbrook, IL
Introduction: The impact of overactive bladder (OAB) on costs due to time lost from work is not well known. The objective of this study was to quantify the direct healthcare costs and indirect costs due to work loss associated with OAB in the United States (US).
Methods: Adults ≥18 years of age with an OAB diagnosis or OAB prescription therapy between 1/1/2008 and 12/31/2013 were identified from the MarketScan® administrative claims databases (index date = qualifying claim date). Patients were required to have ≥12 months of pre- and ≥1 month of post-index continuous enrollment. Data on work loss due to absence and short-term disability (STD) were available for subsets of the overall study population. Each OAB cohort was propensity score-matched to an equivalent number of non-OAB controls. Estimates of total per-patient per-month (PPPM) direct healthcare costs, as well as estimates of indirect costs attributable to absence and STD were modeled using ordinary least squares regression. The level of statistical significance for all tests was set at 0.05.
Results: 110,059 OAB patients were identified, 9.8% of whom had work absence data and 49.3% had STD data. Average adjusted PPPM healthcare costs were significantly higher among OAB patients than non-OAB matched controls ($3,003.42 vs. $1,122.80, p<0.0001). Similarly, among patients with STD eligibility, those with OAB incurred significantly higher PPPM indirect costs attributable to STD compared to non-OAB controls ($114.23 vs. $98.31, p=0.0192) when adjusted within the framework of a two-part model. PPPM indirect costs of work loss due to absence did not differ significantly between patients with OAB and non-OAB matched control patients ($1,412.27 vs. $1,350.56, p=0.4398).
Conclusions: Patients with OAB incurred 2.5 times the healthcare costs of patients without OAB. OAB patients incurred more work loss and costs due to STD than non-OAB controls. Indirect costs attributable to workplace absence, however, did not differ for OAB patients and non-OAB controls.
Source Of Funding: Astellas Pharma, Inc paid Truven Health Analytics, an IBM Company, to carry out this research.
Emily Durden, MA, PhD is Lead Researcher with Truven Health Analytics, an IBM Company. Dr. Durden has more than 15 years of experience conducting and managing health outcomes research studies. Her key expertise is in the design and implementation of studies examining the association between exposures (e.g., socioeconomic conditions, therapeutic interventions, treatment protocols or programs, and diseases) and outcomes (e.g., recovery, remission, survival, healthcare costs, time lost from work). Her research experience includes studies in the clinical areas of mental health, oncology, and osteoporosis, and in cardiovascular, autoimmune, and endocrine disease. Dr. Durden has published peer-reviewed articles in several journals, including the Journal of Managed Care Pharmacy, the Journal of Occupational and Environmental Medicine, and Social Science and Medicine, and has made numerous conference presentations at clinical, social science, and health economics meetings. She has also taught undergraduate courses in social epidemiology, medical sociology, and research methods at the University of Texas at Austin. Dr. Durden holds a doctorate in sociology from the University of Texas at Austin.
Saturday, May 13
9:30 AM – 11:30 AM